. Hulgan et al. present data from a cohort of subjects with CD4+ counts ≥200 cells/mm 3 to evaluate the prognostic significance of CD4+ percentage in this group.
Subjects were at least 16 years of age and had been on their first HAART regimen for at least 30 days. Subjects had a baseline absolute CD4+ lymphocyte count, CD4+ percentage and HIV RNA measurements available within a period of 180 days before or 45 days after the initiation of HAART.
A new opportunistic infection, AIDS-defining illnesses or death after study initiation were considered study events.
Seven hundred and eighty-eight patients were included in the study of which 25% were female and 41% were African American. The median age was 37 years. The median interquartile range for absolute CD4+ lymphocyte count and CD4+ percentage was 225 cells/mm 3 and 17%, respectively.
Fifty-nine percent of individuals were treatment naïve at the beginning, 34% had experience with NRTIs but were on no retroviral therapy at the time of entry, and 7% intensified their NRTI-based therapy at the time of entry. The overall median follow-up was 103 days, and 140 subjects developed an AIDS-defining illness.
Two hundred and sixty-six (74%) of the 360 patients in the <200 CD4+ cells /mm 3 group had a CD4+ lymphocyte percentage <14%. Thirty-six (16%) of 223 individuals who had CD4+ lymphocyte counts >350 cells/mm 3 , had CD4+ lymphocyte percentage <20 %. Individuals with CD4+ counts <200 cells/mm 3 or a percentage <17% had a higher likelihood of progression to an AIDS-defining illness than those with counts ≥200 cells/mm 3 or a percentage >17%. There was a faster progression to AIDS-defining illness or death among individuals, in ≥350 cells/mm 3 , who also had CD4+ percentage <17% compared with subjects with a CD4+ percentage ≥17%. A CD4+ percentage of <17% predicted disease progression with a hazard ratio of 3.57 (95% confidence interval = 1.03-12.34, P = .045).
CD4+ lymphocyte percentage <17%, HIV RNA level, and non-white race were predictors of disease progression or death independent of baseline CD4+ lymphocyte counts.
SIDDIQUI AND POLIS

COMMENTARY
Current guidelines for the initiation of HAART recommend that individuals with HIV viral load >100,000 copies/ml should start therapy at absolute High CD4+ absolute numbers and low results CD4+ percentage are seen in 8-10% of untreated patients. This study does not specifically address these rates. However, discordance was seen in 16% of 223 subjects among those who had CD4 +cell count >350 cells/mm 3 . The study also does not define a specific cutoff value in terms of CD4+ lymphocyte percentage. Because the median CD4+ percentage in their study cohort was 17%, this was chosen as the cutoff value instead of 14%, which is used traditionally to stratify persons into CD4+ percent strata.
This study attempts to understand the role of CD4+ percentage in the management of HIV infection. In the <200 cells/mm 3 strata, the current recommendations are optimal and there seems to be no advantage of utilizing CD4+ percentage. Data from this study suggest that CD4+ percentage may help differentiate those persons with CD4+ cell counts >350cells / mm 3 which may progress more rapidly and may benefit from early therapy.
The P-value of .045 for this relationship is of marginal significance and could be due to the relatively few events that occurred late in the follow-up period. Additionally, 20% of individuals were on a triple nucleoside therapy, which is now considered suboptimal therapy. Though HIV RNA level was an independent predictor of progression among all study participants regardless of baseline absolute CD4+ cell counts, it was not evaluated specifically in the group with CD4+cell counts >350/mm 
SUMMARY
HAART has significantly improved the survival of patients with HIV. This progress is tempered by the need to manage coinfections in these patients with other chronic viruses, especially Hepatitis B and C. Rockstroh et al. present an analysis of hepatitis C virus (HCV) seroprevalance, survival, HIV disease progression, virologic response, and CD4+ cell count recovery based on the HCV serostatus in individuals on HAART from the EuroSIDA cohort.
EuroSIDA enrolled patients from centers in Europe, Israel, and Argentina from 1994 to 2003. Patients were grouped based on HCV serostatus into three categories-unknown, seronegative, and seropositive. HCV viral loads were not routinely obtained. HIV disease progression was defined as a new AIDS-defining illness or death due to any cause.
Patients were followed either from time of entry into the study or from the date of the first HCV antibody test result to their first AIDS-defining illness or death. Those who did not have prospective follow-up were excluded from the analysis, and those who had no clinical events were censored at the date of their last follow-up visit.
A virologic response was identified as a plasma viral load of <500 copies /μl, an immunological response was defined as an increase in CD4+ count of ≥50% and an increase of ≥50 cells/μl after the initiation of HAART. Patients were censored if they did not achieve either response at the time of the last viral load or CD4+ count evaluation. Adjustment was made for factors that are known to effect virologic or immunologic response. Adjustment was not made for changes to the initial HAART regimen or stopping it. CD4+ cell count and HIV viral load were considered categorical variables so that patients with data missing in this regard could be included.
Three thousand and nine hundred and ninety-seven HCV negative individuals and 1960 HCV + individuals were followed. HCV seropositive individuals had been infected with HIV via injection drug use, whereas those who were HCV negative had been predominantly infected via sexual contact. Hepatitis B was more common in the HCV seropositive group. The two groups were comparable with regard to HIV viral load and CD4+ cell count. The proportion of patients with AIDS before or after recruitment was higher in the HCV seronegative group.
Nine hundred and seventeen AIDS-defining illnesses, 819 deaths, 109 liver-related deaths, and 462 non-HIV-related deaths occurred among those with known HCV serostatus. Event rates per 100 PYFU were significantly higher in the HCV seropositive patients than in the seronegative patients. The univariable analysis showed an increased incidence of new AIDS-defining illness or any death in the HCV seropositive individuals, though the multivariate analyses found no such effect. There was a significantly increased incidence of any death in both univariable and multivariable analyses which was largely due to the >10-fold increase in the incidence of liver-disease-related death. Adjustment for HIV viral load did not change the result. When the analyses were repeated for injection drug users (IDUs) there was a significantly increased incidence of liver-disease-related deaths in those infected with HIV-1 and HCV.
The two groups were very similar at HAART was initiation in terms of HIV viral load and CD4+ cell count as well as treatment regimens initiated.
Of the 2015 patients with plasma HIV viral load of >500 copies/ml or unknown 1799 achieved virologic response after HAART (89% in the HCV seronegative group and 91% in the HCV seropositive group). Average time to achieving virologic response was similar in the two groups. Six months after HAART initiation, 55% of subjects in the HCV seronegative and 51% in the HCV seropositive were <500 copies/ml.
Of 2215 patients with known CD4+ cell counts at initiation of HAART 1823 (83% in the HCV seronegative group and 80% in the HCV seropositive group) achieved an increase of >50% in their CD4+ cell count. Two thousand and fifteen subjects achieved an increase of >50cells /μl (91% in the HCV seronegative group and 90% in the HCV seropositive group). The median time to achieving immunologic success was 6 months for both groups. Adjustment for relevant variables did not change the results.
COMMENTARY
Coinfection with HCV is seen in about 30% of HIV-infected individuals. These infections are acquired through the same routes of transmission and are related to similar exposures. The role of coinfections in HIV disease is of particular importance, as optimal means of managing both need to be addressed. Most studies looking at the dynamics of the coinfection have shown that HIV can accelerate HCV-related liver disease. The reverse relationship of HCV on HIV progression, however, is not clear. This study by Rockstroh et al. attempts to clarify this issue. This study suggests that HCV serostatus does not affect HIV disease progression but does increase the risk of liver disease-associated deaths. The immunologic and virologic response to HAART was not affected by HCV serostatus.
There are some limitations to this study. HCV viral loads were not available for many patients. The duration of HCV infection was not considered for its potential impact on the progression of HIV.
Though there was a 10-fold increase in the liver-disease-associated deaths, the proportion of all deaths attributed to liver disease in this group was quite small. The increase in deaths in the HCV coinfected population could also be due to other high-risk behaviors. Treatment for HCV was uncommon, but adjustment for such treatment did not change the results.
As the use of HAART improves the outcome of patients with HIV, it is imperative that we begin to understand the effect of other coinfections in these patients, as they may ultimately be the determinants of prognosis for our patients. This study helps us begin to understand the dynamics of the impact of HCV coinfection on HIV management. Additional work looking at a more comparative cohort in terms of HIV disease stage, HAART regimens and with information regarding HCV disease duration and control is required to further clarify this issue. 
SUMMARY
Persistent infection in resting CD4+ T cells is responsible for the failure to eradicate HIV infection. This proof of concept study evaluates the ability of valproic acid, an inhibitor of histone deacytelase-1 (HDAC1), an enzyme that helps maintain the latency of replication viable virus, in eradicating latent virus from the resting pool of CD4+ T cells.
Four volunteers receiving HAART who had a plasma viral load of <50 copies/ml for at least 2 years had Enfuvirtide, a fusion inhibitor, added to their regimen for 4-6 weeks to prevent the spread of virus in the presence of valproic acid. Valproic acid was then added to their HAART regimens for 3 months at a dose of 500-750 mg twice daily to maintain plasma levels of valproic acid at 50-100 mg/L.
The change in the number of resting CD4+ HIV-infected cells was measured before and after the administration of valproic acid. An ultra sensitive assay capable of detecting as little as one copy of HIV RNA per ml plasma was used to measure the plasma RNA.
In three of the patients, the number of infected cells declined substantially 16-18 weeks after the administration of valproic acid. Plasma HIV RNA levels did not change significantly in any of the patients. Additionally, there was no evidence of immune activation.
The major side effect was anemia, which could be the result of increased levels of AZT in the presence of valproic acid.
COMMENTARY
HIV-infected CD4+ T cells which do not undergo apoptosis during initial infection and immune activation can go into a resting state. HIV genomes integrated within them persist indefinitely as a source of replication viable virus. Though HAART has dramatically improved the clinical outcome for patients with HIV, all patients maintain at least low levels of HIV viremia chronically and require a lifelong commitment to therapy.
The cure for HIV infection would require an effective means to purge these latently infected cells or destroy the viral genomes that have found refuge within them.
This reservoir of cells is not affected by known treatments for the control of HIV. Valproic acid can affect chromatin structure and can induce HIV expression on resting CD4+T cells, which can then make the cells more amenable to apoptosis. This study opens exciting new avenues in HIV research and may be an initial step in changing how HIV infection may be managed in the future. However, much more work is required in terms of characterizing these latently infected cells and the efficacy of valproic acid in affecting this population of cells cloistered in different tissue compartments.
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